Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia

DOI: 10.1016/0006-3223(92)90111-c
Biological Psychiatry, 1992, 32, 293-5.

#	Paper	IF	Citations
18	A simplified method for quantitation of iodine-123 iodobenzamide in human plasma: a technical note. *European Journal of Nuclear Medicine and Molecular Imaging*, **1993**, 20, 373-8		2
17	Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia. *Psychiatry Research - Neuroimaging*, **1994**, 55, 111-8	2.9	7
16	D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. *Journal of Neural Transmission*, **1995**, 99, 173-85	4.3	11
15	IBZM-SPECT during neuroleptic treatment.		
14	Striatal D2 receptor binding in sleep bruxism: a controlled study with iodine-123-iodobenzamide and single-photon-emission computed tomography. *Journal of Dental Research*, **1996**, 75, 1804-10	8.1	85
13	What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas. *Australian and New Zealand Journal of Psychiatry*, **1996**, 30, 195-209	2.6	32
12	[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects. *Psychiatry Research - Neuroimaging*, **1997**, 75, 103-14	2.9	8
11	Occupancy of striatal D(2)-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. *Psychopharmacology*, **1999**, 146, 81-6	4.7	15
10	Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. *Psychiatry Research - Neuroimaging*, **1999**, 90, 31-9	2.9	21
9	[Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics]. *Der Nervenarzt*, **2000**, 71, 373-9	0.5	8
8	Pharmaco-EEG in psychiatry. *Clinical EEG and Neuroscience*, **2006**, 37, 81-98	2.3	44
7	Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. *Current Neuropharmacology*, **2009**, 7, 302-14	7.6	41
6	Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. *Current Neuropharmacology*, **2009**, 7, 315-30	7.6	24
5	In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. *Behavioural Brain Research*, **2009**, 204, 32-66	3.4	104
4	Neurochemical dysfunction in treated and nontreated schizophrenia - a retrospective analysis of in vivo imaging studies. *Reviews in the Neurosciences*, **2014**, 25, 25-96	4.7	20
3	Psychotic Continuum or Distinct Entities: Perspective from Psychopharmacology. **1995**, 31-55		12
2	Erwartungen des Psychiaters an die Rezeptoren-SPECT des Gehirns. **1995**, 72-79		

1 Rezeptordarstellung mit der Single Photonen Emissions Computertomographie (SPECT): Stand der Forschung und Perspektiven. **1996**, 732-737